Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel

Company’s First Distribution Agreement in Middle East

WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Razan Medical & Surgical Equipment Trading LLC (“Razan Medical” or “Razan Medical Trading”) for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market.

“At Razan Medical, we are dedicated to introducing the latest innovations in the medical device industry. Our commitment to advancing wound care — from prevention to healing — has led us to pursue this partnership with Kane,” said Hussain Malkawi, Managing Director of Razan Medical. “Our collaboration will bring forth an exceptional product to the UAE market which will benefit thousands of patients. We are thrilled about this partnership and look forward to a successful and impactful collaboration.”

“Kane continues to deliver on its commitment to commercialization with this first distribution agreement in the Middle East,” said Marc Edwards, President & CEO. “We’re looking forward to partnering with Razan Medical to bring revyve™ to market in the UAE and we are confident that it is in great hands.”

This is Kane’s third distribution agreement for revyve™. Kane had previously announced agreements with ProgenaCare Global LLC for the US wound care market and Salud Pharma S.A. for Colombia, Costa Rica and Panama. Kane also recently announced its intent to commercialize revyve™ in Canada following the obtention of its ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. DispersinB^®, Aledex™, coactiv+™, coactiv+^®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.

About Razan Medical Trading

Established in 2015 by Mr. Hussain Malkawi as the trading arm of Razan Medical Group, Razan Medical Trading serves as a local (UAE) and regional distributor of medical equipment and consumables in the MENA region. With over 30 years of expertise managing multinational companies in the Middle East and Africa, we provide a wealth of knowledge and experience to ensure a visible and influential presence in the region.

For more information:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.